Reagent kit for quantitatively detecting the mutations of epidermal growth factor receptor(egfr)
AssigneeBeijing Accb Biotech Ltd.
InventorsJunpu XU, Zhao Chen, Jun Li
Life of this patent
Estimating the term…
Abstract
The present invention relates to a detection method and a detection kit for EGFR gene mutations, which relates to the therapeutic efficacy of molecular-targeted anti-cancer drugs. Particularly, the present invention relates to a fluorescent quantitative PCR method and kit for detecting mutations at hotspots of EGFR gene, together with the use thereof. The present invention detects the mutations at specific sites of EGFR gene, and can predict the therapeutic efficacy of EGFR tyrosine kinase inhibitors. Therefore, it can provide a guidance to individualize treatments for cancer patients.
Claims15
1-14. (canceled)
An assay kit for quantitatively detecting an EGFR gene mutation, comprising:
- (1) a PCR primer which binds with nucleotides within a sequence under a suitable PCR condition, said sequence having 200 bases and comprising a mutation site of the EGFR gene;
- (2) a probe for fluorescent quantitative PCR, said probe specifically binding to the base sequence at said mutation site of the EGFR gene under a suitable PCR condition;
- and
- (3) a standard comprising a wild-type plasmid, mutant plasmid, or both a wild-type plasmid and a mutant plasmid, said wild-type plasmid comprising a wild-type EGFR sequence, and said mutant plasmid comprising a mutant EGFR sequence.
A standard, comprises a wild-type plasmid, a mutant plasmid, or both a wild-type plasmid and a mutant plasmid, said wild-type plasmid comprising a wild-type EGFR sequence, and said mutant plasmid comprising a mutant EGFR sequence.
Dependencies are inferred from the claim text.